These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34396494)

  • 1. Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment.
    Asker B; Jawad R; Asreah R; Jamal H; Jassem A; Inaya MA; Baker HA; Kozma S; Mansour E; McNamara B; Miller R; Darlington O; McEwan P; Sugrue DM; Jarallah H
    Pharmacoeconomics; 2021 Nov; 39(11):1327-1341. PubMed ID: 34396494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
    Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
    Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
    Mohamed Z; Scott N; Nayagam S; Rwegasha J; Mbwambo J; Thursz MR; Brown AS; Hellard M; Lemoine M
    Int J Drug Policy; 2022 Jan; 99():103458. PubMed ID: 34624732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India.
    Chugh Y; Premkumar M; Grover GS; Dhiman RK; Teerawattananon Y; Prinja S
    BMJ Open; 2021 Feb; 11(2):e042280. PubMed ID: 33589457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of hepatitis C virus screening strategies by birth cohort in Italy.
    Kondili LA; Gamkrelidze I; Blach S; Marcellusi A; Galli M; Petta S; Puoti M; Vella S; Razavi H; Craxi A; Mennini FS;
    Liver Int; 2020 Jul; 40(7):1545-1555. PubMed ID: 32078234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?
    Manca F; Robinson E; Dillon JF; Boyd KA
    Int J Drug Policy; 2020 Aug; 82():102811. PubMed ID: 32585583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
    McEwan P; Ward T; Yuan Y; Kim R; L'italien G
    Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
    Younossi Z; Blissett D; Blissett R; Henry L; Younossi Y; Beckerman R; Hunt S
    Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
    Kim DY; Han KH; Jun B; Kim TH; Park S; Ward T; Webster S; McEwan P
    PLoS One; 2017; 12(1):e0167770. PubMed ID: 28060834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness of HCV testing strategies for hepatitis C elimination in general population in China].
    Liu PC; Xu D; Ding GW; Zhao L; Yu JJ; Liu ZF; Li J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2024 Mar; 45(3):464-472. PubMed ID: 38514325
    [No Abstract]   [Full Text] [Related]  

  • 15. Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation.
    Fang K; Wang HL; Lin Y; Zheng L; Li S; Wu J
    Public Health; 2024 Mar; 228():186-193. PubMed ID: 38387115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
    Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
    Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and cost-effectiveness of a simplified treatment model with direct-acting antivirals for chronic hepatitis C in Cambodia.
    Walker JG; Mafirakureva N; Iwamoto M; Campbell L; Kim CS; Hastings RA; Doussett JP; Le Paih M; Balkan S; Marquardt T; Maman D; Loarec A; Coast J; Vickerman P
    Liver Int; 2020 Oct; 40(10):2356-2366. PubMed ID: 32475010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of hepatitis C virus (HCV) point-of-care assay for HCV screening.
    Koo V; Tian F; Wong WWL
    Liver Int; 2022 Apr; 42(4):787-795. PubMed ID: 34847288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.
    Selvapatt N; Ward T; Harrison L; Lombardini J; Thursz M; McEwan P; Brown A
    Liver Int; 2017 Mar; 37(3):345-353. PubMed ID: 27566283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.